InvestorsHub Logo
Followers 2
Posts 429
Boards Moderated 0
Alias Born 07/13/2016

Re: None

Friday, 09/23/2016 10:54:00 AM

Friday, September 23, 2016 10:54:00 AM

Post# of 38634
If you go to Briefingwire.com, you will see that anyone can post a release on anything and it will get distributed across the internet for free. In this case, the author is identified as "Doug B.". So, I would say that the possibility that Doub B. is intentionally manipulating the share price might be meaningfully greater than zero. If so, I hope the SEC catches up with him (should be pretty easy for them to do - just get his info from Briefingwire.com) and punishes him appropriately.

One thing is for sure from my perspective, Doug B. is almost certainly not a legitimate source.

That being said, there are many things that actually could happen that would be very positive for the stock, an acquisition being one of them. In fact, an acquisition may be the best way out for the Odidi's given the cash crunch the company faces. If Odidi truly wants to pursue the very interesting drugs he has developed, he needs money to do so, and a lot of it. IF he stays independent, he will need a really attractive partnership deal to do justice to what he has developed. I hope such a partnership is the way this thing goes as shareholders will likely do the best under that scenario in the long run. But the Odidi's could sell the company, gain access to the needed monetary and scientific resources to continue their work and get a lucrative contract that gives them further personal financial upside while shareholders would be left with smaller gains.